Hope for Patients: the EU Approved a New Drug Against the Deadliest Form of Cancer
6 Articles
6 Articles
The European Commission has authorised the marketing of Daraxonrasib in the European Union. The medicinal product is intended for adults with metastatic pancreatic cancer who have already received at least one previous treatment line.
(Adnkronos) - EU's green light on the drug of hope against metastatic pancreatic cancer. "The European Commission (Ce) approved Rasonque (daraxonrasib) for the treatment of adult patients with adenocarcinoma...
Final green light for the U.S. drug that increases survival by 6 months (on average) for patients with metastatic pancreatic cancer. Uncognized relapse on Lombardy, had bought it for one patient only
The European Commission has authorised the use of a new medicine for the treatment of metastatic pancreatic cancer in adults who have already undergone previous treatments, according to official announcement.
The approval is valid in the European Union countries as well as in Iceland, Norway and Liechtenstein. Availability will depend on national decisions on pricing and coverage of treatment costs.
The European Commission has approved Rasonque, a new medicine for adults whose pancreatic cancer has spread to other parts of the body. This gives them a new treatment option with a previously limited choice of treatments. The medicine is taken once a day as a tablet and is intended for patients who have already received at least one cancer treatment. The same medicine was previously approved in August...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium






